-
Innovation Ranking
NewInnovation Ranking – Bellicum Pharmaceuticals Inc
Bellicum Pharmaceuticals, Inc. (Bellicum) is a clinical stage biopharmaceutical company, that develops cellular immunotherapies for the treatment of cancer. The company develops its product candidates through its chemical induction of dimerization technology platforms in the areas of cellular immunotherapy including hematopoietic stem cell transplantation, CAR T cell therapy and TCR cell therapies. Bellicum’s lead pipeline candidate includes BPX-501, an adjunct T cell therapy intended for the treatment of leukemias, lymphomas and genetic blood diseases. The company also develops pipeline products...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BNT-411 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BNT-411 in Small-Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BNT-411 in Small-Cell Lung Cancer Drug Details: SC-1 (BNT-411) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy For GD2 Expressing Solid Tumors in Neuroblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy For GD2 Expressing Solid Tumors in Neuroblastoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene Therapy For GD2 Expressing Solid Tumors...
-
Product Insights
NewGraft Versus Host Disease (GVHD) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Graft Versus Host Disease (GVHD) Clinical Trial Market Report Overview Graft versus host disease (GVHD) clinical trial market research report provides top line data relating to the clinical trials on Graft Versus Host Disease (GVHD). The report includes an overview of trials count and their average enrollment in top countries conducted globally. The report includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status, and sponsor type. The report also provides prominent...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BPX-401 in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BPX-401 in Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BPX-401 in Non-Hodgkin Lymphoma Drug Details: BPX-401 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BPX-401 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BPX-401 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BPX-401 in Acute Lymphocytic Leukemia (ALL,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BGB-16673 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BGB-16673 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BGB-16673 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details: BGB-16673 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JANX-008 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JANX-008 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JANX-008 in Non-Small Cell Lung Cancer Drug Details: JANX-008...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IC9 CAR.19 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IC9 CAR.19 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IC9 CAR.19 in Diffuse Large B-Cell Lymphoma Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IC9 CAR.19 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IC9 CAR.19 in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IC9 CAR.19 in Mantle Cell Lymphoma Drug Details: iC9 CAR.19...